Type 2 diabetes
A metabolic disease characterized by chronically elevated blood sugar due to insulin resistance and inadequate insulin secretion. GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are first-line treatments.
Frequently Asked Questions
What is Type 2 diabetes?
Why is Type 2 diabetes important in peptide research?
Related Terms
A condition where cells respond poorly to insulin, requiring the pancreas to produce more insulin to maintain normal blood sugar. A precursor to type 2 diabetes. GLP-1 agonists improve insulin sensitivity.
Metabolic syndromeA cluster of conditions including central obesity, elevated blood sugar, high blood pressure, and abnormal cholesterol that together increase the risk of heart disease, stroke, and type 2 diabetes.
GLP-1Glucagon-like peptide-1, an incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. The therapeutic target of blockbuster drugs semaglutide, tirzepatide, and liraglutide.
Related Peptide Profiles
A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and weight management (Wegovy). Reduces appetite and slows gastric emptying.
TirzepatideA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound). Achieves 20–25% body weight reduction in clinical trials.
LiraglutideA GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza) and weight management (Saxenda). Administered as a daily injection.